Last reviewed · How we verify
Homeopathic medication Plumbum metallicum
Homeopathic medication Plumbum metallicum is a Small molecule drug developed by Federal University of São Paulo. It is currently FDA-approved.
Plumbum metallicum is a homeopathic medication currently marketed by the Federal University of São Paulo. The key composition patent for Plumbum metallicum is set to expire in 2028, providing a period of exclusive market protection. The primary risk is the lack of clear primary indication and revenue data, which may limit its market appeal and investment attractiveness.
At a glance
| Generic name | Homeopathic medication Plumbum metallicum |
|---|---|
| Sponsor | Federal University of São Paulo |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Homeopathic medication Plumbum metallicum CI brief — competitive landscape report
- Homeopathic medication Plumbum metallicum updates RSS · CI watch RSS
- Federal University of São Paulo portfolio CI